RxDoctor Payments Data

Richard Fatica, MD

Nephrology · Cleveland, OHNPI 1447366174

Payments from drug & device makers

$8,776in general payments, 2019–2025

Across 24 payments — averaging $365.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Enterprises LLC$4K
  • Sanofi$4K
  • Otsuka America Pharmaceutical, Inc.$215
  • Novartis$165
  • AstraZeneca$150
  • Nxstage Medical, Inc.$106
  • plus $206 from 5 others

What the payments were for

  • Consulting fees$7,81189%
  • Speaking & faculty fees$1502%
  • Food & beverage$7018%
  • Education$1141%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,776 in reported general payments places this provider in the 80th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio

Medicare billing

Part B allowed, 2024
$68,877
Medicare patients
221
Services billed
488

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AfinitorEverolimus11$202,065
Everolimus27$70,919
VelphoroSucroferric Oxyhydroxide20$61,037
LokelmaSodium Zirconium Cyclosilicate24$32,734
EliquisApixaban34$25,306
Valganciclovir Hcl52$16,949
FarxigaDapagliflozin Propanediol21$14,011
Tacrolimus50$6,894
Sevelamer Carbonate20$4,553
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim285$2,722
Prednisone306$2,244
Mycophenolate Mofetil16$2,186
Cinacalcet Hcl18$1,775
Nifedipine ErNifedipine19$1,217
Gentamicin Sulfate24$824

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisAfinitor$165$202,06511 claims
Fresenius USA Marketing, Inc.Velphoro$17$61,03720 claims
AstraZenecaLokelma, Farxiga$150$46,74545 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 450 nephrology providers in Ohio.

Other nephrology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →